G Carlsson1, A Fasth. 1. Department of Pediatrics, Sunderby Hospital, Luleå, Sweden. goran048@hotmail.com
Abstract
UNLABELLED: In 1956 Rolf Kostmann reported on six children with severe neutropenia associated with a block in myelopoiesis at the promyelocyte/myelocyte stage and an autosomal recessive inheritance. He named the new syndrome infantile genetic agranulocytosis. Today it is known as Kostmann's syndrome or severe congenital neutropenia. In 1975 an additional 10 cases from northern Sweden were published. This article reports on the only long-term survivor from the 1975 report plus another five patients born after 1975 who belong to the original "Kostmann family". Treatment and survival have changed dramatically since Kostmann's first publication. In the pre-antibiotic era, Kostmann's syndrome was inevitably fatal during the first year of life. CONCLUSION: Since the introduction of recombinant human granulocyte colony-stimulating factor (G-CSF) about 10 y ago, most patients now enjoy a normal life span and a greatly improved quality of life. Although the threat of death has disappeared, patients still have problems with infections, especially chronic gingivitis and periodontitis. In other groups of severe neutropenia, not related to the original "Kostmann family", an increased incidence of myeloid leukaemia has been observed. However, in this small cohort none of the children on chronic G-CSF therapy have developed malignancies.
UNLABELLED: In 1956 Rolf Kostmann reported on six children with severe neutropenia associated with a block in myelopoiesis at the promyelocyte/myelocyte stage and an autosomal recessive inheritance. He named the new syndrome infantile genetic agranulocytosis. Today it is known as Kostmann's syndrome or severe congenital neutropenia. In 1975 an additional 10 cases from northern Sweden were published. This article reports on the only long-term survivor from the 1975 report plus another five patients born after 1975 who belong to the original "Kostmann family". Treatment and survival have changed dramatically since Kostmann's first publication. In the pre-antibiotic era, Kostmann's syndrome was inevitably fatal during the first year of life. CONCLUSION: Since the introduction of recombinant humangranulocyte colony-stimulating factor (G-CSF) about 10 y ago, most patients now enjoy a normal life span and a greatly improved quality of life. Although the threat of death has disappeared, patients still have problems with infections, especially chronic gingivitis and periodontitis. In other groups of severe neutropenia, not related to the original "Kostmann family", an increased incidence of myeloid leukaemia has been observed. However, in this small cohort none of the children on chronic G-CSF therapy have developed malignancies.
Authors: Vahagn Makaryan; Elisabeth A Rosenthal; Audrey Anna Bolyard; Merideth L Kelley; Jennifer E Below; Michael J Bamshad; Kathryn M Bofferding; Joshua D Smith; Kati Buckingham; Laurence A Boxer; Julia Skokowa; Karl Welte; Deborah A Nickerson; Gail P Jarvik; David C Dale Journal: Hum Mutat Date: 2014-05-21 Impact factor: 4.878
Authors: M Melin; M Entesarian; G Carlsson; D Garwicz; C Klein; B Fadeel; M Nordenskjöld; J Palmblad; J I Henter; N Dahl Journal: Biochem Biophys Res Commun Date: 2006-12-20 Impact factor: 3.575
Authors: Ewa Sicinska; Young-Mi Lee; Judith Gits; Hirokazu Shigematsu; Qunyan Yu; Vivienne I Rebel; Yan Geng; Christopher J Marshall; Koichi Akashi; David M Dorfman; Ivo P Touw; Piotr Sicinski Journal: Mol Cell Biol Date: 2006-09-05 Impact factor: 4.272